You are here: Industry Insights > Cancer Drugs Fund

News List

NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund europeanpharmaceuticalreview
April 22, 2020
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
NICE recommends AstraZeneca’s Imfinzi through Cancer Drugs Fund By Allie Nawrat pharmaceutical-technology
April 03, 2019
The UK’s National Institute of Health and Care Excellence (NICE) has published its final guidance for AstraZeneca’s Imfinzi (durvalumab), in which it recommends the immunotherapy for use by the NHS through the Cancer Drugs Fund.
NICE nod for breast cancer delay drug pharmatimes
April 02, 2019
The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for NHS use within the Cancer Drugs Fund (CDF).
NICE backs use of Bristol-Myers Squibb's Opdivo via Cancer Drugs Fund for completely resected melanoma firstwordpharma
December 02, 2018
The National Institute for Health and Care Excellence issued a final appraisal document on Friday recommending use of Bristol-Myers Squibb's Opdivo (nivolumab) within the Cancer Drugs Fund (CDF) as an option for the adjuvant treatment of completely resect
Bayer's Nexavar approved for primary liver cancer by NICE pharmatimes
August 11, 2017
Nexavar, funded through the Cancer Drugs Fund, has been the only option of advanced liver cancer patients in England.